Table 2_Leadless pacemaker in atrioventricular block patients with specific indications: a systematic review.docx

The overall incidence of adverse events in patients receiving leadless pacemakers was low. Among these, 16 studies provided complication data for the AVB subgroup and were included in the meta-analysis. The results showed that, compared with the control group, leadless pacemakers did not significantly reduce the risk of adverse events in AVB patients (RR = 1.41, 95% CI: 0.43–4.60, P = 0.57).

Subgroup analysis by device type demonstrated no statistically significant differences in adverse event risks compared to traditional pacemakers for either single-chamber ventricular leadless pacemakers (RR = 0.26, 95% CI: 0.03–2.01, P = 0.20) or AV-synchronous/dual-chamber leadless pacemakers (RR = 2.16, 95% CI: 0.76–6.17, P = 0.15), with no significant interaction between subgroups. In the single-arm rate analysis, five cohort studies reported an adverse event rate of 14% (95% CI: 0.04–0.24); after applying the Freeman-Tukey transformation to eleven single-arm studies, the adverse event rate was 1.15% (95% CI: 0.26%–2.67%).</p>Conclusion<p>In patients with atrioventricular block, leadless pacemakers demonstrate no significant difference in the risk of adverse events compared with conventional pacemakers, with lower complication rates and favorable clinical feasibility.</p>